SCHEMBL6226567

SCHEMBL6226567

O=Cc1ccc(-c2ccccc2F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTPRC P08575 1/20 0.43
PTPN1 P18031 1/20 0.43
CYP2A6 P11509 1/20 0.41
DRD1 P21728 3/20 0.40
ERN1 O75460 1/20 0.40
KIF11 P52732 3/20 0.39
KDM4E B2RXH2 1/20 0.39
PTGS2 P35354 1/20 0.39
RAB9A P51151 1/20 0.39
PTGER4 P35408 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
DRD3 P35462 1/20 0.39
EGFR P00533 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6852399 0.91 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2CYP2A6KIF11KDM4E
SCHEMBL6854203 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2CYP2A6KIF11KDM4E
SCHEMBL257774 0.84 MEN1 (0.46) ALDH1A1SMN1; SMN2PTPRCPTPN1CYP2A6
SCHEMBL29887017 0.83 KDM4E (0.50) ALDH1A1SMN1; SMN2ERN1KDM4EPTGS2
SCHEMBL14879562 0.83 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KIF11KDM4EPTGS2
SCHEMBL16055941 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2PTPRCPTPN1ERN1
SCHEMBL14879528 0.80 CYP2A6 (0.45) ALDH1A1SMN1; SMN2CYP2A6KDM4ERAB9A
SCHEMBL28055988 0.79 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2ERN1RAB9A
SCHEMBL14334580 0.79 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2ERN1KDM4EPTGER4
SCHEMBL11672577 0.79 ALDH1A1 (0.41) ALDH1A1PTPRCPTPN1KDM4EPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768491-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2016-12-21 EP disclosed
US-9266908-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2016-02-23 US disclosed
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed
EP-2768491-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS Mars, Incorporated (US) 2014-08-27 EP disclosed
WO-2013059437-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2013-04-25 WO disclosed
EP-1590321-A2 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY Sanofi-Aventis (FR) 2005-11-02 EP disclosed
WO-2004067498-A2 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT1 ALDH1A1 681/4885SMN1; SMN2 3139/4885PTPRC 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.